Mindfulness meditation reduces anxiety as much as a common antidepressant drug, study finds

Mindfulness meditation reduces anxiety as much as a common antidepressant drug, study finds


Mindfulness meditation is as effective at reducing anxiety as a commonly prescribed antidepressant, according to a study published in a major journal on Wednesday.

The study, led by researchers at Georgetown University Medical Center, is the first randomized clinical trial to compare the effectiveness of mindfulness meditation with the antidepressant escitalopram. The results were published in JAMA Psychiatry, a peer-reviewed journal.

The adult participants in the mindfulness group practiced 45-minute daily meditations using a few different techniques they learned at weekly classes. They also went on daylong weekend retreats.

The meditation techniques included breath awareness; body scanning, in which attention is directed to one body part at a time; and mindful movement, in which stretching and movements bring attention to the body.

Participants in the antidepressant group received 10mg of escitalopram daily the first week, and then took 20mg daily for the rest of the study if the pill was well tolerated. There were 102 patients in the mindfulness group and 106 in the antidepressant group. Escitalopram is sold under the brand names Lexapro and Cipralex, among others.

After monitoring the two groups for eight weeks, researchers found that people using mindfulness meditation saw their anxiety improve nearly as much as people who were taking the antidepressant.

Dr. Elizabeth Hoge, lead author on the study, said the findings support physicians recommending mindfulness meditation as an alternative to antidepressants for some patients. Many people worry that antidepressants will interfere with their daily lives and others start taking medications but stop.

Hoge, who is director of Georgetown University’s Anxiety Disorders Research Program, said the study also provides evidence for insurers to cover mindfulness meditation as a treatment for anxiety.

Anxiety disorders are the most common type of mental illness, affecting about 301 million people around the world, according to a February study published in Lancet Psychiatry.



Source

Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
Health

Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly

Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry. The new strategy, “Metabolic Frontier 2030,” comes as Zealand […]

Read More
Eli Lilly to build  billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs
Health

Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs

Eli Lilly CEO David A. Ricks speaks at a press conference at Generation Park in Houston, Monday, Sept. 23, 2025. The company announced plans for a $6.5 billion biomanufacturing plant in north Houston. (Raquel Natalicchio/Houston Chronicle via Getty Images) Raquel Natalicchio | Houston Chronicle | Getty Images Eli Lilly on Tuesday said it will spend […]

Read More
A biotech stock for investors scared to invest in the risky industry
Health

A biotech stock for investors scared to invest in the risky industry

Citigroup thinks investors should consider Ligand Pharmaceuticals for a more conservative bet on the biotech industry. The bank initiated the biotech stock at a buy rating and price target of $270, implying upside of 46% from Ligand’s Monday closing price of $184.67. Shares have soared nearly 79% this year. LGND YTD mountain LGND YTD chart […]

Read More